Related Experiment Videos
[Adenoviral p53 gene therapy for human lung cancer]
Toshiyoshi Fujiwara1, Noriaki Tanaka
1Division of Surgical Oncology, Dept. of Surgery, Okayama University Graduate School of Medicine and Dentistry.
Abstract:
Recent advances in molecular biology have fostered remarkable insights into the molecular basis of neoplasms. This new understanding of cancer pathogenesis suggests that restoration of the function of critical gene products could halt or reverse these mechanisms, thus having a therapeutic effect in cancer. The tumor suppressor p53 gene has been implicated in many inherited and sporadic forms of malignancy in humans. A number of preclinical experiments have demonstrated that restoration of the wild-type p53 function in the cancer cell by gene transfer is sufficient to cause antitumor effects such as cell-cycle arrest and induction of apoptosis. This approach has entered initial clinical testing and provided intriguing information about the intratumoral administration of an adenovirus vector expressing the wild-type p53 gene in non-small cell lung cancer patients.
Insights
Restoring tumor suppressor p53 gene function via gene transfer shows promise for cancer therapy. Early clinical trials in lung cancer patients demonstrate potential antitumor effects, offering new therapeutic avenues.
Area of Science:
- Molecular Biology
- Oncology
- Cancer Genetics
Context:
- Neoplasms arise from complex molecular alterations.
- The tumor suppressor p53 gene is crucial in many human cancers.
- Gene therapy offers a novel approach to cancer treatment.
Purpose:
- To explore the therapeutic potential of restoring wild-type p53 function in cancer cells.
- To investigate the antitumor effects of p53 gene transfer.
- To evaluate the clinical efficacy of p53-based gene therapy in non-small cell lung cancer.
Summary:
- Advances in molecular biology reveal cancer's molecular underpinnings.
- Restoring critical gene product function, like the p53 tumor suppressor, can halt or reverse cancer progression.
- Preclinical studies show p53 gene transfer induces cell-cycle arrest and apoptosis, leading to antitumor effects.
Impact:
- Paves the way for targeted cancer therapies by correcting genetic defects.
- Offers a potential strategy to halt or reverse malignancy by restoring normal gene function.
- Provides early clinical insights into p53 gene therapy for non-small cell lung cancer, guiding future research.